Use of Low Molecular Weight Heparin and Aminocaproic Acid in Chronic DIC Associated with Prostate Cancer- A Case Report

Disseminated Intravascular Coagulopathy (DIC) is the most common coagulopathy in patients with prostate cancer. Though rare, it could be fatal without treatment. Literature suggests that there is significant activation of fibrinolytic pathway. Pathophysiology of DIC in patients with prostate cancer is not completely understood. We present here a case of chronic DIC in a patient with metastatic androgen independent prostate cancer. His DIC was managed successfully with a combination of aminocaproic acid and low weight molecular heparin. The use of low molecular weight heparin may make management of chronic DIC in prostate cancer more feasible in an out patient setting.

Download Full-text

Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.05.074 ◽

2004 ◽

Vol 22 (13) ◽

pp. 2532-2539 ◽

Cited By ~ 247

Author(s):

William L. Dahut ◽

James L. Gulley ◽

Philip M. Arlen ◽

Yinong Liu ◽

Katherine M. Fedenko ◽

...

Keyword(s):

Prostate Cancer ◽

Molecular Weight ◽

Phase Ii ◽

Low Molecular Weight Heparin ◽

Phase Ii Trial ◽

Low Molecular Weight ◽

Randomized Phase Ii ◽

The Impact ◽

Docetaxel Group ◽

Androgen Independent

Purpose Both docetaxel and thalidomide have demonstrated activity in androgen-independent prostate cancer (AIPC). We compared the efficacy of docetaxel to docetaxel plus thalidomide in patients with AIPC. Methods Seventy-five patients with chemotherapy-naïve metastatic AIPC were randomly assigned to receive either docetaxel 30 mg/m2 intravenously every week for 3 consecutive weeks, followed by a 1-week rest period (n = 25); or docetaxel at the same dose and schedule, plus thalidomide 200 mg orally each day (n = 50). Prostate-specific antigen (PSA) consensus criteria and radiographic scans were used to determine the proportion of patients with a PSA decline, and time to progression. Results After a median potential follow-up time of 26.4 months, the proportion of patients with a greater than 50% decline in PSA was higher in the docetaxel/thalidomide group (53% in the combined group, 37% in docetaxel-alone arm). The median progression-free survival in the docetaxel group was 3.7 months and 5.9 months in the combined group (P = .32). At 18 months, overall survival in the docetaxel group was 42.9% and 68.2% in the combined group. Toxicities in both groups were manageable after administration of prophylactic low-molecular-weight heparin in the combination group. Conclusion In this randomized phase II trial, the addition of thalidomide to docetaxel resulted in an encouraging PSA decline rate and overall median survival rate in patients with metastatic AIPC. After the prophylactic low-molecular-weight heparin was instituted to prevent venous thromboses, the combination regimen was well tolerated. Larger randomized trials are warranted to assess the impact of this combination.

Download Full-text

Use of Low Molecular Weight Heparin and Aminocaproic Acid in Chronic DIC Associated with Prostate Cancer- A Case Report

TSW Urology ◽

10.1100/tswurol.2007.46 ◽

2007 ◽

Vol 2 ◽

pp. 27-29

Author(s):

Keisuke Shirai ◽

Uzair B Chaudhary

Keyword(s):

Prostate Cancer ◽

Molecular Weight ◽

Case Report ◽

Low Molecular Weight Heparin ◽

Aminocaproic Acid ◽

Low Molecular Weight

Download Full-text

Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer

Hematology ◽

10.1182/asheducation-2016.1.206 ◽

2016 ◽

Vol 2016 (1) ◽

pp. 206-207 ◽

Cited By ~ 3

Author(s):

Lisa Baumann Kreuziger ◽

Michael Streiff

Keyword(s):

Prostate Cancer ◽

Molecular Weight ◽

Pulmonary Embolism ◽

Low Molecular Weight Heparin ◽

Femoral Vein ◽

Stage Iv ◽

Low Molecular Weight ◽

Vein Thrombosis ◽

Patients With Cancer ◽

Deep Vein

Abstract A 68-year-old man developed a right femoral vein deep vein thrombosis and bilateral pulmonary embolism while receiving chemotherapy for stage IV prostate cancer. His creatinine at diagnosis is 1.4 mg/dL, with an estimated clearance of 63 mL/min. In patients with cancer, should low-molecular-weight heparin treatment be dosed according to weight, or adjusted using anti-Xa levels?

Download Full-text

Venous malformation: update on aetiopathogenesis, diagnosis and management

Phlebology The Journal of Venous Disease ◽

10.1258/phleb.2009.009041 ◽

2010 ◽

Vol 25 (5) ◽

pp. 224-235 ◽

Cited By ~ 160

Author(s):

A Dompmartin ◽

M Vikkula ◽

L M Boon

Keyword(s):

Low Molecular Weight Heparin ◽

Fibrinogen Level ◽

Current Knowledge ◽

Venous Malformation ◽

Vascular Anomalies ◽

Low Molecular Weight ◽

Disseminated Intravascular Coagulopathy ◽

Genetic Studies ◽

Intravascular Coagulopathy ◽

D Dimer

The aim of this review was to discuss the current knowledge on aetiopathogenesis, diagnosis and therapeutic management of venous malformations (VMs). VMs are slow-flow vascular anomalies. They are simple, sporadic or familial (cutaneomucosal VMs or glomuvenous malformations), combined (e.g. capillaro-venous and capillaro-lymphaticovenous malformations) or syndromic (Klippel–Trenaunay, blue rubber bleb naevus and Maffucci). Genetic studies have identified causes of familial forms and of 40% of sporadic VMs. Another diagnostic advancement is the identification of elevated d-dimer level as the first biomarker of VMs within vascular anomalies. Those associated with pain are often responsive to low-molecular-weight heparin, which should also be used to avoid disseminated intravascular coagulopathy secondary to intervention, especially if fibrinogen level is low. Finally, development of a modified sclerosing agent, ethylcellulose–ethanol, has improved therapy. It is efficient and safe, and widens indications for sclerotherapy to sensitive and dangerous areas such as hands, feet and periocular area.

Download Full-text